Skip to main content
Premium Trial:

Request an Annual Quote

Prevencio, Microsoft Ink Agreement for AI-Based Cardiac Blood Tests

NEW YORK – Prevencio said Tuesday that it has inked an agreement with Microsoft for the sale of Prevencio's cardiac blood tests.

The deal, leveraging Microsoft’s Azure AI-based computing cloud platform and marketing expertise, enables Microsoft Healthcare's salesforce to sell Prevencio's artificial intelligence-based HART cardiac blood tests.

Financial and other terms of the deal were not disclosed.

As part of the collaboration, Microsoft will sell Kirkland, Washington-based Prevencio's cardiac blood tests into the software giant's existing customer base, including hospitals, life science companies, and contract research organizations.

"Microsoft’s efforts will complement our corporate focus on offering our HART tests to concierge physicians," Provencio's CEO Rhonda Rhyne said in a statement. In July, the firm plans to launch its HART CVE test for a patient’s one-year risk of heart attack, stroke, or cardiac death, and HART CAD for diagnosis of heart disease.